Anzeige
Meldung des Tages: 307 Meter Gold: Dieser Treffer könnte diese Goldaktie jetzt neu bewerten

PAVmed Aktie News

Aktie
WKN:  ISIN:  US70387R5028 US-Symbol:  PAVM
8,09 $
-0,56 $
-6,47%
6,7611 € 28.01.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

PAVmed News

20.03.25 - PR Newswire
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening PR Newswire
18.03.25 - PR Newswire
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-​Reviewed Publication PR Newswire
11.03.25 - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on March 25, 2025 PR Newswire
10.03.25 - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 PR Newswire
05.03.25 - PR Newswire
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering PR Newswire
04.03.25 - PR Newswire
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering PR Newswire
27.02.25 - PR Newswire
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD PR Newswire
25.02.25 - PR Newswire
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire
24.02.25 - PR Newswire
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
PAVmed and Subsidiary Veris Health Complete Private Placement Financing PR Newswire
20.02.25 - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health PR Newswire
18.02.25 - PR Newswire
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement PR Newswire
06.02.25 - PR Newswire
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference PR Newswire

Newssuche

Videos

newspaper
27.01.26 +1,29%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »